JP2024520713A5 - - Google Patents

Info

Publication number
JP2024520713A5
JP2024520713A5 JP2023574679A JP2023574679A JP2024520713A5 JP 2024520713 A5 JP2024520713 A5 JP 2024520713A5 JP 2023574679 A JP2023574679 A JP 2023574679A JP 2023574679 A JP2023574679 A JP 2023574679A JP 2024520713 A5 JP2024520713 A5 JP 2024520713A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
inhibitor
combination
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520713A (ja
Filing date
Publication date
Priority claimed from GBGB2107907.4A external-priority patent/GB202107907D0/en
Application filed filed Critical
Publication of JP2024520713A publication Critical patent/JP2024520713A/ja
Publication of JP2024520713A5 publication Critical patent/JP2024520713A5/ja
Pending legal-status Critical Current

Links

JP2023574679A 2021-06-02 2022-06-01 Mettl3阻害剤とさらなる抗がん剤を含む併用療法 Pending JP2024520713A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2107907.4 2021-06-02
GBGB2107907.4A GB202107907D0 (en) 2021-06-02 2021-06-02 Combination therapies
PCT/GB2022/051400 WO2022254216A1 (en) 2021-06-02 2022-06-01 Combination therapies comprising a mettl3 inhibitor and a further anticancer agent

Publications (2)

Publication Number Publication Date
JP2024520713A JP2024520713A (ja) 2024-05-24
JP2024520713A5 true JP2024520713A5 (cg-RX-API-DMAC7.html) 2025-06-06

Family

ID=76741389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574679A Pending JP2024520713A (ja) 2021-06-02 2022-06-01 Mettl3阻害剤とさらなる抗がん剤を含む併用療法

Country Status (8)

Country Link
US (1) US20240277715A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346814A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520713A (cg-RX-API-DMAC7.html)
CN (1) CN117460508A (cg-RX-API-DMAC7.html)
AU (1) AU2022285928A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221771A1 (cg-RX-API-DMAC7.html)
GB (1) GB202107907D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022254216A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025530847A (ja) * 2022-09-16 2025-09-17 北京華益健康薬物研究中心 Mettl3阻害剤化合物、その医薬組成物及び用途
JP2026514449A (ja) 2023-03-30 2026-05-11 ノヴァリックス 新規mettl3阻害剤及び治療におけるその使用
WO2025121807A1 (ko) * 2023-12-08 2025-06-12 인제대학교 산학협력단 Ezh2 저해제 및 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물
KR20250088372A (ko) * 2023-12-08 2025-06-17 인제대학교 산학협력단 Btk 분해제와 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물
WO2025237957A1 (en) * 2024-05-14 2025-11-20 Institut Curie Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
WO2026017844A1 (en) * 2024-07-19 2026-01-22 Epics Therapeutics Combination therapies comprising a mettl3 inhibitor and a bcl2 inhibitor
WO2026017846A1 (en) * 2024-07-19 2026-01-22 Epics Therapeutics Piperidine derivatives as mettl3 inhibitors for the treatment of carcinomas
CN118948887B (zh) * 2024-07-26 2026-03-27 新乡市中心医院(新乡中原医院管理中心) Mettl3抑制剂联合化疗药顺铂对宫颈癌的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
US20210164992A1 (en) * 2018-07-23 2021-06-03 New York University Compositions and methods related to innate response to dna and regulation of interferon-beta
US20200081533A1 (en) 2018-09-07 2020-03-12 Microsoft Technology Licensing, Llc Wearable device having regions of varying stiffnesses
WO2020201773A1 (en) * 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
WO2021003330A1 (en) * 2019-07-03 2021-01-07 Children's Medical Center Corporation Inhibiting the rna methyltransferase mettl3 or its interaction with eif3h to suppress oncogene translation and tumorigenesis
US12195458B2 (en) * 2019-12-02 2025-01-14 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors

Similar Documents

Publication Publication Date Title
Dai et al. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Tsilimigras et al. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective
Song et al. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
Cho et al. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
JP6356134B2 (ja) 免疫応答の増強
Dong et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
Schneider et al. Phase I study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma: evidence of tumor hypomethylation as an indicator of major histopathologic response
JP2022500419A5 (cg-RX-API-DMAC7.html)
Zhang et al. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
JP2020525483A5 (cg-RX-API-DMAC7.html)
Rousseau et al. Lipopolysaccharide-induced toll-like receptor 4 signaling enhances the migratory ability of human esophageal cancer cells in a selectin-dependent manner
CN110536702A (zh) 使用hsp90抑制剂治疗癌症的方法
Lu et al. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6
WO2017035453A1 (en) Compositions and methods for treating solid tumors
JP2021530444A5 (cg-RX-API-DMAC7.html)
RU2019130325A (ru) ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ
Müller et al. 5-Azacytidine/5-Azacitidine
JP2021516236A (ja) 急性骨髄性白血病および関連状態を処置する方法
TW201929882A (zh) E3連接酶抑制劑和溶瘤病毒在用於製備抗腫瘤藥物的用途
Khan et al. Antibody-directed therapies: toward a durable and tolerable treatment platform for CTCL
Alyamany et al. Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management
WO2017200492A1 (en) Method of treating cancer
FI3888647T3 (fi) Ezh1/2-kaksoisestäjän sisältävä farmaseuttinen koostumus käytettäväksi yhdistelmälääkkeenä
Zelent et al. Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy
TWI284643B (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione